Zelira’s share price has experienced a significant surge following a study revealing that their cannabinoid drug has surpassed a multibillion-dollar product by Pfizer in terms of performance. Leave a comment
Zelira Therapeutics, a company listed on the Australian Securities Exchange (ASX), witnessed a remarkable 230% surge in its share price. This surge followed the release of study results demonstrating that Zelira’s cannabinoid medication for relieving diabetic nerve pain exhibited superior efficacy compared to Pfizer’s Lyrica.
About the Author
Our deep love of plants and fascination with Cannabis has enabled over 25 years of successful small-scale Marijuana cultivation from indoor hydroponics, greenhouses, and outdoor growing set-ups.
As Cannabis laws around the world change, *we support the movement toward freedom of choice for responsible, consenting adults who wish to experience the joy and wonder of growing a Cannabis plant.
